Literature DB >> 24372611

Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.

J C Hopewell1, U Seedorf, M Farrall, S Parish, T Kyriakou, A Goel, A Hamsten, R Collins, H Watkins, R Clarke.   

Abstract

OBJECTIVES: Observational and genetic studies have shown that lipoprotein(a) [Lp(a)] levels and apolipoprotein(a) [apo(a)] isoform size are both associated with coronary heart disease (CHD) risk, but the relative independence of these risk factors remains unclear. Clarification of this uncertainty is relevant to the potential of future Lp(a)-lowering therapies for the prevention of CHD.
METHODS: Plasma Lp(a) levels and apo(a) isoform size, estimated by the number of kringle IV (KIV) repeats, were measured in 995 patients with CHD and 998 control subjects. The associations between CHD risk and fifths of Lp(a) levels were assessed before and after adjustment for KIV repeats and, conversely, the associations between CHD risk and fifths of KIV repeats were assessed before and after adjustment for Lp(a) levels.
RESULTS: Individuals in the top fifth of Lp(a) levels had more than a twofold higher risk of CHD compared with those in the bottom fifth, and this association was materially unaltered after adjustment for KIV repeats [odds ratio (OR) 2.05, 95% confidence interval (CI) 1.38-3.04, P < 0.001]. Furthermore, almost all of the excess risk was restricted to the two-fifths of the population with the highest Lp(a) levels. Individuals in the bottom fifth of KIV repeats had about a twofold higher risk of CHD compared with those in the top fifth, but this association was no longer significant after adjustment for Lp(a) levels (OR 1.13, 95% CI 0.77-1.66, P = 0.94).
CONCLUSIONS: The effect of KIV repeats on CHD risk is mediated through their impact on Lp(a) levels, suggesting that absolute levels of Lp(a), rather than apo(a) isoform size, are the main determinant of CHD risk.
© 2013 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  apolipoprotein(a); coronary heart disease; isoform size; lipoprotein(a)

Mesh:

Substances:

Year:  2014        PMID: 24372611     DOI: 10.1111/joim.12187

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  12 in total

1.  Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records.

Authors:  Hao Yu Chen; Line Dufresne; Hannah Burr; Athithan Ambikkumar; Niko Yasui; Kevin Luk; Dilrini K Ranatunga; Rachel A Whitmer; Mark Lathrop; James C Engert; George Thanassoulis
Journal:  JAMA Cardiol       Date:  2018-01-01       Impact factor: 14.676

Review 2.  Applications of microfluidics and microchip electrophoresis for potential clinical biomarker analysis.

Authors:  Jayson V Pagaduan; Vishal Sahore; Adam T Woolley
Journal:  Anal Bioanal Chem       Date:  2015-04-09       Impact factor: 4.142

3.  Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes.

Authors:  Kirsten A Berk; Reyhana Yahya; Adrie J M Verhoeven; Jeanette Touw; Frank P Leijten; Elisabeth F van Rossum; Vincent L Wester; Mirjam A Lips; Hanno Pijl; Reinier Timman; Gertraud Erhart; Florian Kronenberg; Jeanine E Roeters van Lennep; Eric J G Sijbrands; Monique T Mulder
Journal:  Diabetologia       Date:  2017-04-06       Impact factor: 10.122

4.  Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease.

Authors:  Frank van Buuren; Dieter Horstkotte; Cornelius Knabbe; Dennis Hinse; Klaus Peter Mellwig
Journal:  Clin Res Cardiol Suppl       Date:  2017-03

5.  Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.

Authors:  Dick C Chan; Gerald F Watts; Blai Coll; Scott M Wasserman; Santica M Marcovina; P Hugh R Barrett
Journal:  J Am Heart Assoc       Date:  2019-04-02       Impact factor: 5.501

6.  Elevated lipoprotein(a) and risk of coronary heart disease according to different lipid profiles in the general Chinese community population: the CHCN-BTH study.

Authors:  Chunyue Guo; Han Cao; Guangliang Shan; Wei Zhao; Han Zhang; Kaijun Niu; Ze Cui; Naijun Tang; Kuo Liu; Li Pan; Xiaoyan Han; Zhengfang Wang; Ge Meng; Jixin Sun; Anqi Shan; Yuxiang Yan; Huijing He; Zhiyuan Xu; Yajing Cao; Wenjuan Peng; Yanyan Sun; Yunyi Xie; Xiaohui Liu; Bingxiao Li; Fuyuan Wen; Ling Zhang
Journal:  Ann Transl Med       Date:  2021-01

Review 7.  The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.

Authors:  Yongzheng Lu; Xiaolin Cui; Li Zhang; Xu Wang; Yanyan Xu; Zhen Qin; Gangqiong Liu; Qiguang Wang; Kang Tian; Khoon S Lim; Chris J Charles; Jinying Zhang; Junnan Tang
Journal:  Aging Dis       Date:  2022-04-01       Impact factor: 6.745

Review 8.  The role of lipoprotein (a) in chronic kidney disease.

Authors:  Jemma C Hopewell; Richard Haynes; Colin Baigent
Journal:  J Lipid Res       Date:  2018-01-29       Impact factor: 5.922

9.  Association of BAX hypermethylation with coronary heart disease is specific to individuals aged over 70.

Authors:  Limei Zhang; Huihui Ji; Yi Huang; Haochang Hu; Bin Li; Yong Yang; Hang Yu; Xiaoying Chen; Wenxia Li; Fang Liu; Shi Wang; Chunming Wang; Ke Chen; Yingchun Bao; Haibo Liu; Shiwei Duan
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

Review 10.  Exploring the potential impact of nutritionally actionable genetic polymorphisms on idiopathic male infertility: a review of current evidence.

Authors:  Sinda Mahbouli; Charlotte Dupont; Yaelle Elfassy; Eric Lameignère; Rachel Levy
Journal:  Asian J Androl       Date:  2021 Sep-Oct       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.